The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis

Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis

January 6, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ATLANTA—The COAST-X (NCT02757352) study evaluated the efficacy and safety of ixekizumab in patients with non-radiographic axial spondyloarthritis (axSpA). In November, the primary results of this 52-week, randomized, double-blind, placebo-controlled, phase 3 study were presented at the 2019 ACR/ARP Annual Meeting.1

You Might Also Like
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
  • FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis
Also By This Author
  • Rheumatology Drug Updates

To participate, patients (n=303) with non-radiographic axSpA had to meet the Assessment of Spondyloarthritis International Society (ASAS) criteria, with a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and total back pain scores of greater than 4 at baseline. Patients also had to have objective signs of inflammation with the presence of sacroiliitis on MRI or elevated CRP levels of more than 5 mg/L, as well as an intolerance or lack of response to non-steroidal anti-inflammatory drugs (NSAIDs).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients received either 80 mg of ixekizumab every four weeks, 80 mg of ixekizumab every two weeks or placebo for up to Week 52. After Week 16, background medication changes or escape to open-label ixekizumab administered every two weeks was allowed at the investigators’ discretion. Conventional background medications included NSAIDs, csDMARDs, analgesics and low-dose corticosteroids. These patients were considered nonresponsive to the treatment.

The study’s primary endpoint was an improvement in the signs and symptoms of non-radiographic axSpA measured by the ASAS40 at Weeks 16 and 52. Secondary endpoints included the improvement in Ankylosing Spondylitis Disease Activity Score (ASDAS), significant improvement in BASDAI scores and the proportion of patients who achieved low disease activity (an ASDAS less than 2.1). Other secondary end points were a significant improvement in sacroiliac joint inflammation as assessed by MRI at Week 16 and a significant improvement in the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) score at both Weeks 16 and 52.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
All primary and major secondary endpoints were met during the study. The first statistically significant improvements in ASAS40 rates were seen for both ixekizumab-treated regimen patients as early as Week 1. At Weeks 16 and 52, ASAS40 responses in ixekizumab-treated patients were clinically and statistically significant compared with placebo-treated patients (P<0.01). At Week 52, 30% of patients who received 80 mg of ixekizumab every four weeks achieved an ASAS40 response. Additionally, 31% of patients who received 80 mg of ixekizumab every two weeks achieved an ASAS40 response. Only 13% of placebo-treated patients achieved an ASAS40 response.

From baseline to Week 16, the PCS score significantly differed between placebo-treated patients and ixekizumab-treated patients. This finding was evident as early as Week 4 and maintained through Week 52. Patients on both ixekizumab treatment regimens had significantly greater changes from baseline in disease activity, functional status, and sacroiliac joint, Spondyloarthritis Research Consortium of Canada scores compared with placebo-treated patients at Weeks 16 and 52.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: 2019 ACR/ARP Annual Meeting, axial spondyloarthritis (SpA), ixekizumab, non-radiographic axial spondyloarthritis

You Might Also Like:
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
  • FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)